Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine recombinant quadrivalent - Merck

X
Drug Profile

Human papillomavirus vaccine recombinant quadrivalent - Merck

Alternative Names: Gardasil; Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine - Merck; Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine - Merck; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Merck; q HPV; Quadrivalent human papillomavirus vaccine - Merck; Silgard; V 501

Latest Information Update: 05 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL; The University of Queensland
  • Developer Banyu; Chongqing Zhifei Biological Products; CSL; Merck & Co; Merck Sharp & Dohme; National Cancer Institute (USA); The EMMES Corporation; University of Arkansas System; University of California at San Francisco
  • Class Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Condylomata acuminata; Gynaecological cancer; Human papillomavirus infections
  • Phase III Penile cancer

Most Recent Events

  • 22 May 2024 PharmaJet withdrew phase II trial in healthy volunteers (In adolescents, In children) in Indonesia (IM, Intradermal) due to change in landscape of HPV treatment (NCT06142461)
  • 30 Oct 2023 Merck completes a Phase-III clinical trial in Human papillomavirus infections (Prevention, In children, In adolescents, In adults) in China (IM)(NCT03493542)
  • 27 Oct 2021 University of Alabama completes the phase II trial in Human-papillomavirus-infections (In children, In adolescent, In adults, Prevention) in USA (NCT01492582)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top